The ZDSD, a New Rat Model of Metabolic Syndrome: Evidence of Cardiovascular Disease

Objective: To evaluate retinol and β-carotene serum levels and their relationship with risk factors for cardiovascular disease in individuals with morbid obesity, resident in Rio de Janeiro. Methodology: Blood serum concentrations of retinol and β-carotene of 189 morbidly obese individuals were assessed. The metabolic syndrome was identified according to the criteria of the National Cholesterol Education Program (NCEP) and World Health Organization (WHO). Lipid profile, insulin resistance, basal insulin, glycemia, blood pressure, and anthropometry and their correlation with retinol and β-carotene serum levels were evaluated. Results: Metabolic syndrome diagnosis was observed in 49.0% of the sample. Within this percentage the levels of β-carotene were significantly lower when body mass index increased. Serum retinol didn't show this behavior. Serum retinol inadequacy in patients with metabolic syndrome (61.3%), according to WHO criterion, was higher (15.8%) than when the whole sample was considered (12.7%). When metabolic syndrome was diagnosed by NCEP criterion, β-carotene inadequacy was higher (42.8%) when compared to the total sample (37.5%). There was a significant difference between average β-carotene values of patients with and without metabolic syndrome (p=0.048) according to the classification of the NCEP. Lower values were found in patients with metabolic syndrome. Conclusion: Considering the vitamin A contribution in antioxidant protection, especially when risk factors for cardiovascular disease are present, it is suggested that great attention be given to morbidly obese. This could aid in prevention and treatment of cardiovascular disease, which affects a significant part of the population.

Download Full-text

Cardiovascular Risk Assessement in Osteoporotic Patients Using Osteoprotegerin as a Reliable Predictive Biochemical Marker

Ibn AL- Haitham Journal For Pure and Applied Science ◽

10.30526/2017.ihsciconf.1798 ◽

2018 ◽

pp. 253

Author(s):

Noora Wael Rasheed ◽

Ooroba Jameel Taresh

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Cardiovascular Risk ◽

Serum Level ◽

Biochemical Markers ◽

Hdl Cholesterol ◽

Predictive Marker ◽

Serum Levels ◽

Arterial Calcification ◽

The Metabolic Syndrome

Some studies indicated a relationship between increased serum levels of osteoprotegerin with arterial calcification and as a result, it leads to the risk of cardiovascular disease. In our study group we selected patients with osteoporosis, with similar age and body mass index for the assessment of the relationship between cardiovascular disease and osteoprotegerin serum level. We took into account the analysis of correlation and association between the presence of distinct patterns of atherosclerosis and associated diseases like high blood pressure, diabetes mellitus, low HDL cholesterol, increased LDL cholesterol, increased triglycerides and was the case of presence of any type of dyslipidemia, in case of pre-existent treatment. Objective of study was the assessment of osteoprotegerin value as predictive marker for cardiovascular and metabolic risk in osteoporotic patients. Our results showed significant correlations of parathyroid hormone, osteocalcin and biochemical markers of bone with glucose metabolism and lipid were found in our research, maintaining crosstalk between calcium and biochemical markers of bone and cardiovascular risk. The serum level of Osteoprotegerin has been shown to have a large predictive value for the metabolic syndrome as a cardiovascular risk standard in patients with osteoporosis. The osteoprotegerin serum levels were increased in the patients with metabolic syndrome as a protective response facing the atherosclerotic lesions.

Download Full-text

Faculty Opinions recommendation of Metabolic syndrome and the risk of cardiovascular disease in older adults.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13896.471401 ◽

2006 ◽

Author(s):

Wilbert Aronow

Keyword(s):

Cardiovascular Disease ◽

Older Adults ◽

Metabolic Syndrome

Download Full-text

Hyperuricemia and Cardiovascular Disease

Current Pharmaceutical Design ◽

10.2174/1381612825666190408122557 ◽

2019 ◽

Vol 25 (6) ◽

pp. 700-709 ◽

Cited By ~ 4

Author(s):

Shuangshuang Zhang ◽

Yong Wang ◽

Jinsong Cheng ◽

Ning Huangfu ◽

Ruochi Zhao ◽

...

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Chronic Kidney Disease ◽

Uric Acid ◽

Kidney Disease ◽

Kidney Stones ◽

Treatment Plan ◽

Circulatory System ◽

Special Focus ◽

Positive Effects

Purine metabolism in the circulatory system yields uric acid as its final oxidation product, which is believed to be linked to the development of gout and kidney stones. Hyperuricemia is closely correlated with cardiovascular disease, metabolic syndrome, and chronic kidney disease, as attested by the epidemiological and empirical research. In this review, we summarize the recent knowledge about hyperuricemia, with a special focus on its physiology, epidemiology, and correlation with cardiovascular disease. This review also discusses the possible positive effects of treatment to reduce urate levels in patients with cardiovascular disease and hyperuricemia, which may lead to an improved clinical treatment plan.

Download Full-text